Brain+

24/05/2023

BRAIN+ SHOWCASED AT DANISH DEMENTIA DAYS & ALTENPFLEGE IN GERMANY

- Brain+ was featured at The Dementia Days in Copenhagen, the most important annual dementia event in Denmark with over 1,000 municipal dementia coordinators present
- Brain+ was selected as one of the most promising new elderly care technology start-ups at the annual German elderly care conference, Altenpflege
- Conference showcasing is essential to build product awareness and relationships with target customers – and has confirmed growing interest in the Brain+ dementia products

Following the market introduction of the first commercial version of its digital dementia care product, CST-Therapist Companion, in Denmark in Q4 2022 and in Germany in Q2 2023, Brain+ has scaled its go-to-market activities.

Brain+ showcased at Danish Dementia Days & Altenpflege in Germany Following the market introduction of the first commercial version of its digital dementia care product, CST-Therapist Companion, in Denmark in Q4 2022 and in Germany […]

10/05/2023

BRAIN+ CLOSES ITS SECOND SALES CONTRACT FOR CST
- Therapist Companion with a dementia care center in Gladsaxe municipality

- Gladsaxe is the second Danish municipality to have opened for use of CST – Therapist Companion to support Cognitive Stimulation Therapy (CST) for people with dementia
- Two contract closings less than 6 months after CST – Therapist Companion was commercially introduced is promising, considering a typical municipal sales cycle of 12-24 months
- Denmark is an important reference market for Brain+ with CST gaining widespread recognition

The sales contract is a 3-year contract, giving therapists in the municipal dementia care facility, Bakkegården demensboliger, in Gladsaxe access to use the product until June 2026.

Brain+ closes its second sales contract for CST  Therapist Companion with a dementia care center in Gladsaxe municipality Brain+ announces to have closed a second sales contract for the company’s new digital dementia product, CST […]

09/05/2023

Kim Baden-Kristensen (CEO) and Hanne Leth Hillman (Interim CFO) explain the current Brain+ rights issue.

Topics discussed:

- Turbulent market conditions

- Existing shareholders

- What you get in the rights issue

- Use of funds

- The business case of Brain+

To learn more about the rights issue, visit this address:

https://www.brain-plus.com/rights_issue_2023/

21/04/2023

MALTESER HILFSDIENST AND BRAIN+ BEGIN COLLABORATION
to offer people with dementia access to CST in special dementia cafes in Germany

- The first step is a 2-months pilot offering of Brain+’ German version of CST-Therapist Companion in one Malteser dementia café to support care services for people with dementia
- Malteser Hilfsdienst is a key provider of dementia services, and the potential is to expand the use of CST-Therapist Companion to the organization’s 100 dementia cafés around Germany

The Malteser Hilfsdienst is one of Germany’s major charitable service providers with over 1 million members and sponsors, and the organization is a major player in offering services to people with dementia and their caregivers, to a large extent via 100 special dementia cafés, called ‘Café Malta’, located across Germany.

Malteser Hilfsdienst and Brain+ begin collaboration to offer people with dementia access to CST in special dementia cafes in Germany Brain+ and Malteser Hilfsdienst has started a collaboration to help people with dementia in Germany. The Malteser Hilfsdienst is one of Germany’s […]

28/03/2023

Germany sets a new digitalization strategy.



This month the German Ministry of Health’s shared its new healthcare digitalization strategy, “Gemeinsam Digital”, and a vision for an integrated digital health ecosystem in Germany. The country’s strong focus on digital solutions represents an excellent opportunity for Brain+ and other suppliers of digital therapeutics by enabling easier access to Europe’s largest healthcare market.





- Germany represents a large market potential for Brain+’ digital dementia therapeutics.

- Brain+ is preparing for the commercial introduction of its first digital dementia product, CST-Therapist Companion, in Germany in the 2nd quarter of 2023.

- As an important healthcare reference country, Germany’s strong digitalization commitment sets the stage for more rapid adoption of digital therapeutics across Europe.

Read more: https://www.brain-plus.com/new-digital-health-strategy-in-germany/

Germany sets a new digitalization strategy further supporting the adoption of digital therapeutics in Europe’s largest healthcare market This month the German Ministry of Health’s shared its new healthcare digitalization strategy, “Gemeinsam Digital”, together with a vision for an inte...

24/03/2023

A key finding from the recently released 2nd systematic Cochrane review (Woods et al., 2023) is the confirmation that medication combined with CST results in significantly larger benefits over and above that of medication alone.

More specifically, patients that take part in CST demonstrate improvements in general cognition, Quality of Life and communication, to name just a few.

- CST, in combination with cholinesterase inhibitors, is shown to be more effective against dementia in Alzheimer’s disease (AD) than medicine alone.

- This is promising for combining Brain+ CST products with AD medicine in multi-modal treatment plans to improve health outcomes for patients.

- Combination treatments could enhance the value of product portfolios for pharmaceutical companies and could thus lead to strategic partnerships for Brain+.

Read more: https://www.brain-plus.com/cognitive-stimulation-therapy-cst-enhances-the-effects-of-alzheimers-disease-medicine/

medication combined with CST results in significantly larger benefits over and above that of medication alone. More specifically, patients that take part in CST demonstrate improvements in general cognition, Quality of Life and communication, to name just a few.

20/03/2023

BRAIN+ EXPANDS ITS FIRST SALES CONTRACT, close to doubling it

- This is important because it shows the potential for growing engagements with customers after an initial contract has been established
- The contractual expansion happens only 3 months after the closing of the sale in December 2022
- Denmark is an important reference market for Brain+, and the total municipal market potential for the full future suite of Brain+ CST-based products is estimated at 200 million DKK

In December 2023 Brain+ closed its first sales contract with Herning Municipality, and Herning has chosen to expand that contract, nearly doubling the contractual size.

Brain+ expands its first sales contract close to doubling it In December 2023 Brain+ closed its first sales contract with Herning Municipality, and Herning has chosen to expand that contract, nearly doubling the contractual size. […]

14/03/2023

RESPECTED DEMENTIA EXPERTS AND BRAIN+ GET EU GRANT TO RESEARCH how to optimize digital at-home treatments for people with dementia

- The grant covers research into the two main therapeutic technologies of Brain+, digitalized CST, and CCT.
- The grant will also examine the hypothesized synergy effects of combining CST with CCT, which is a key research step for the third Brain+ product in the pipeline, ‘CST-for-MCI’.
- University of Gothenburg is hosting the grant, which has a budget of €48,405, and is funded by the EU Joint Programme – Neurodegenerative Disease Research.

The research goal is to develop a framework for delivering digitized interventions for people with dementia, with a special focus on Cognitive Stimulation Therapy (CST) and Computerized Cognitive Training (CCT), the two main therapeutic technologies of Brain+.

Respected dementia experts and Brain+ get EU grant to research how to optimize digital at-home treatments for people with dementia The EU Joint Programme – Neurodegenerative Disease Research has granted 496,000SEK (or 48,405 euros) to […]

06/03/2023

💯 Det tager et stærkt team at lykkes med at skabe en ny kategori af behandling til demens og Alzheimer's. Bertil har rykket stærkt siden han tiltrådte som finansdirektør i Brain+ og har professionaliseret finans og økonomifunktionen, samtidig med at være en dygtig strategisk-økonomisk analytiker, som hjælper os med at træffe de rigtige valg på kommercielle og andre strategiske spørgsmål! ... En velfortjent udvælgelse til at være blandt Talent-100. 💯

Læs mere her.

02/03/2023

NEW COCHRANE REVIEW CONFIRMS CST

- Reviews carried out by Cochrane Review Groups are recognized worldwide as the highest standard in evidence-based healthcare.
- The review shows cognitive benefits of CST corresponding to a 6-month delay in cognitive decline in mild to moderate dementia, and additional improvements in communication and social interaction.
- Provides further solid support for the increased adoption of CST as a non-pharmaceutical dementia therapy worldwide and for Brain+’ CST-based suite of digital dementia products.

The systematic review further strengthens the scientific evidence base of CST, the main therapy for dementia that Brain+ is pioneering the digitalization of in the form of Digital Therapeutics for dementia.

New Cochrane review confirms the benefit and relevance of Cognitive Stimulation Therapy (CST) for people with dementia A 2nd systematic Cochrane review, ‘Cognitive stimulation to improve cognitive functioning in people with dementia’ (Woods et al., 2023), […]

28/02/2023

Brain+ featured as 'Start-up of the Day' 🏅 by Innovation Origins... and speaking of origins, the interview here covers the origin story of Brain+ and how the idea for Brain+ emerged and the journey to where we are today 🏞... It has been a path with many turns and twists (pivots if you talk start-up lingo), it has been extremely challenging and stressful at times, and is very rewarding and exciting also! Building a business is not for the faint-hearted, but there is never a shortage of opportunities to learn, and so if you get excited by being challenged and growing personally this life could be for you ;-)

Best wishes,
Kim

Dementia is one of the leading causes of death worldwide. Brain+ is developing digital therapy that counteracts the cognitive decline.

21/02/2023

Showcasing our digital dementia products at the Danish-Japanese Welfare and Health Tech Business Conference



Important opportunity for Brain+ to present its innovative digital solutions for better care and treatment of Alzheimer’s and other types of dementia to key Japanese industry and academic stakeholders.



With a large aging population and more than 4.6 million people living with dementia, Japan has a strong focus on new treatment options and represents a highly attractive market opportunity for Brain+.

Read more: https://www.brain-plus.com/matsumae-business-cup/

Brain+ showcases its digital dementia products At the Danish-Japanese Welfare and Health Tech Business Conference Brain+ is part of a group of Danish welfare and health tech companies that have been invited to present their […]